Biography
Nadeem is the Founder and President of the Eisai Center for Genetics Guided Dementia Discovery (G2D2) – an autonomous “spin-in” biotech exclusively focused on harnessing human genetics, data sciences, and precision chemistry. G2D2 is located at a new, tailored-designed 50,000 Sqft facility in Cambridge, MA. Nadeem sits on the US National Academies of Science, Engineering and Medicine’s Roundtable on Genomics & Precision Health (within which he co-leads the Precision Therapeutics working group), and has served as Chair - US Institute of Medicine Workshop on “Drug Discovery From Genetic Bioresources”; Chair - World CNS Summit; Chair - Festival of Genomics; Chair - External Advisory Board, NIA Longevity Genomics Study; Industry Lead - ADNI Genetics; and Scientific Board, IMI-EPAD. Before joining Eisai, Nadeem was Senior Director, Head of Population Research & Head of Cardiometabolic Genetics, at Pfizer Inc. Prior to working in the pharmaceutical industry, Nadeem was tenured faculty at the School of Clinical Medicine, University of Cambridge (UK).

Biography
Amer Haider was the CEO and Co-Founder of Doctella.com, a company that provides cloud-based remote data capture from wearables and medical-grade equipment with digital CarePrograms™ that automates remote care delivery. Doctella was acquired by Masimo (NASDAQ:MASI) in 2018. Prior to Doctella, Amer was part of the executive team at Cavium (NASDAQ: CAVM). Amer has been involved in starting, investing, growing and acquiring companies that have raised over $100 million in venture capital, have been acquired for over $200M and have had a successful public offering creating combined equity value of over $2 billion. He holds 9 issued patents in the areas of security and digital processors. Amer with his wife Munira operates two non-profits related to club-foot and achondroplasia, congenital conditions of their children (www.pehlaqadam.org, www.growingstronger.org). Amer has an MS in Numerical Simulation and an MBA from U of IL at Urbana Champaign.

Biography
Alicia Martin is a population and statistical geneticist. Her research examines the role of human history in shaping global genetic and phenotypic diversity. Given vast Eurocentric study biases, she investigates the generalizability of knowledge gained from large-scale genetic studies across globally diverse populations. She is particularly focused on ensuring that the translation of genetic technologies via polygenic risk does not exacerbate health disparities induced by these study biases. Towards this end, she is also developing statistical methods and resources for multi-ethnic studies and underrepresented populations. Her work is currently supported by an NIH K99/R00 Pathway to Independence Award.

Biography
Peter Goodhand is a senior executive and board member in the global health sector. Prior to GA4GH, he was the President and Chief Executive Officer of the Canadian Cancer Society, Canada's largest health charity. Before joining the charitable sector, Goodhand had a 20-year career in the global medical technology industry, including strategic leadership roles with multinational healthcare companies such as American Cyanamid and Johnson & Johnson; Board Chair and President of Canada’s Medical Device Industry association (MEDEC); and as the founding Managing Director and the Board Chair of the Health Technology Exchange (HTX). Goodhand is currently Co-Chair of the International 100K+ Cohorts Consortium (IHCC), Co-Chair of the Medical and Scientific Advisory Board of Global Genes, a member of the Global Genomic Medicine Collaboration (G2MC) Steering Committee, and a member of the Occupational Cancer Research Centre Steering Committee.

Biography
Dr. Nelson joined Deerfield in 2019 as Vice President of Genetics and Genomics at Deerfield Discovery and Development, LLC. Dr. Nelson joined Deerfield from GlaxoSmithKline, where he spent almost 15 years and was most recently the Head of Genetics. Prior to GlaxoSmithKline, Dr. Nelson was the Director of Biostatistics at Sequenom. He began his career as an information scientist at Esperion Therapeutics. Dr. Nelson was an Adjunct Associate Professor of Biostatistics at the University of North Carolina from 2010 to 2016. He holds a Ph.D. in Human Genetics and M.A. in Statistics from the University of Michigan, and obtained his B.S. in Molecular Biology from Brigham Young University.